Cargando…
P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430953/ http://dx.doi.org/10.1097/01.HS9.0000970616.80080.6b |
| _version_ | 1785091083310465024 |
|---|---|
| author | Terpos, Evangelos Ntanasis-Stathopoulos, Ioannis Gavriatopoulou, Maria Malandrakis, Panagiotis Fotiou, Despina Migkou, Magdalini Theodorakakou, Foteini Spiliopoulou, Vasiliki Syrigou, Rodanthi Eleutherakis-Papaiakovou, Evangelos Gkolfinopoulos, Stavros Manousou, Kyriaki Kastritis, Efstathios Dimopoulos, Meletios A. |
| author_facet | Terpos, Evangelos Ntanasis-Stathopoulos, Ioannis Gavriatopoulou, Maria Malandrakis, Panagiotis Fotiou, Despina Migkou, Magdalini Theodorakakou, Foteini Spiliopoulou, Vasiliki Syrigou, Rodanthi Eleutherakis-Papaiakovou, Evangelos Gkolfinopoulos, Stavros Manousou, Kyriaki Kastritis, Efstathios Dimopoulos, Meletios A. |
| author_sort | Terpos, Evangelos |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430953 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104309532023-08-17 P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL Terpos, Evangelos Ntanasis-Stathopoulos, Ioannis Gavriatopoulou, Maria Malandrakis, Panagiotis Fotiou, Despina Migkou, Magdalini Theodorakakou, Foteini Spiliopoulou, Vasiliki Syrigou, Rodanthi Eleutherakis-Papaiakovou, Evangelos Gkolfinopoulos, Stavros Manousou, Kyriaki Kastritis, Efstathios Dimopoulos, Meletios A. Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430953/ http://dx.doi.org/10.1097/01.HS9.0000970616.80080.6b Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Terpos, Evangelos Ntanasis-Stathopoulos, Ioannis Gavriatopoulou, Maria Malandrakis, Panagiotis Fotiou, Despina Migkou, Magdalini Theodorakakou, Foteini Spiliopoulou, Vasiliki Syrigou, Rodanthi Eleutherakis-Papaiakovou, Evangelos Gkolfinopoulos, Stavros Manousou, Kyriaki Kastritis, Efstathios Dimopoulos, Meletios A. P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL |
| title | P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL |
| title_full | P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL |
| title_fullStr | P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL |
| title_full_unstemmed | P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL |
| title_short | P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL |
| title_sort | p928: ocular adverse events and functional impact in transplant ineligible, newly diagnosed multiple myeloma patients treated with belantamab mafodotin, lenalidomide and dexamethasone in a phase 1/2 trial |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430953/ http://dx.doi.org/10.1097/01.HS9.0000970616.80080.6b |
| work_keys_str_mv | AT terposevangelos p928ocularadverseeventsandfunctionalimpactintransplantineligiblenewlydiagnosedmultiplemyelomapatientstreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT ntanasisstathopoulosioannis p928ocularadverseeventsandfunctionalimpactintransplantineligiblenewlydiagnosedmultiplemyelomapatientstreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT gavriatopouloumaria p928ocularadverseeventsandfunctionalimpactintransplantineligiblenewlydiagnosedmultiplemyelomapatientstreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT malandrakispanagiotis p928ocularadverseeventsandfunctionalimpactintransplantineligiblenewlydiagnosedmultiplemyelomapatientstreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT fotioudespina p928ocularadverseeventsandfunctionalimpactintransplantineligiblenewlydiagnosedmultiplemyelomapatientstreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT migkoumagdalini p928ocularadverseeventsandfunctionalimpactintransplantineligiblenewlydiagnosedmultiplemyelomapatientstreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT theodorakakoufoteini p928ocularadverseeventsandfunctionalimpactintransplantineligiblenewlydiagnosedmultiplemyelomapatientstreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT spiliopoulouvasiliki p928ocularadverseeventsandfunctionalimpactintransplantineligiblenewlydiagnosedmultiplemyelomapatientstreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT syrigourodanthi p928ocularadverseeventsandfunctionalimpactintransplantineligiblenewlydiagnosedmultiplemyelomapatientstreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT eleutherakispapaiakovouevangelos p928ocularadverseeventsandfunctionalimpactintransplantineligiblenewlydiagnosedmultiplemyelomapatientstreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT gkolfinopoulosstavros p928ocularadverseeventsandfunctionalimpactintransplantineligiblenewlydiagnosedmultiplemyelomapatientstreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT manousoukyriaki p928ocularadverseeventsandfunctionalimpactintransplantineligiblenewlydiagnosedmultiplemyelomapatientstreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT kastritisefstathios p928ocularadverseeventsandfunctionalimpactintransplantineligiblenewlydiagnosedmultiplemyelomapatientstreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial AT dimopoulosmeletiosa p928ocularadverseeventsandfunctionalimpactintransplantineligiblenewlydiagnosedmultiplemyelomapatientstreatedwithbelantamabmafodotinlenalidomideanddexamethasoneinaphase12trial |